The necessary role of an efficient tumor immunotherapy by MHC Ⅱ expression on amateur APCs  

作　　者：Jiaxin Zhong Xiaorong Lin Hai Hu 

机构地区：[1]Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat‐sen Memorial Hospital,Sun Yat‐sen University,Guangzhou,Guangdong,China [2]Department of Oncology,Sun Yat‐sen Memorial Hospital,Sun Yat‐sen University,Guangzhou,Guangdong,China [3]Diagnosis and Treatment Center of Breast Diseases,Shantou Central Hospital,Shantou,Guangdong,China [4]Department of Breast Medical Oncology,Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China [5]Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou,Zhejiang,China

出　　处：《Malignancy Spectrum》2024年第3期147-161,共15页肿瘤学全景(英文)

基　　金：supported by grants from the National Key R&D Program of China (2022YFC3401001);the National Natural Science Foundation of China (82025026 and 82230091 to H.H.);the Key R&D Program of Zhejiang (2024C03160)

摘　　要：Antigen presentation, as the initial step in inducing the activation of T lymphocytes, plays a crucial role in antitumor response. Studies concentrating on major histocompatibility complex class Ⅱ(MHC Ⅱ) molecules and the activated CD4^(+)helper T(Th) cells have gained popularity in light of the past limited efficacy of MHC Ⅰ-activated CD8^(+)T cells alone. In general,MHC Ⅱ is canonically expressed by professional antigen-presenting cells(pAPCs), yet attempts to increase antigen presentation by dendritic cell(DC) activation have mostly been unsuccessful. In recent years, a number of studies have found that a variety of cells, including cancer cells,fibroblasts, vascular endothelial cells(VECs), and lymphoid stromal cells(LSCs), are considered amateur APCs(aAPCs) and can express MHC Ⅱ molecules, which have piqued the interest of researchers. These groups vastly outnumber DCs or macrophages, and it has been confirmed that they also qualify as antigen-presenting complexes that are functionally related to conventional pAPCs. Herein, we will review current research regarding the antigen presentation process of MHC Ⅱ, its advances in APC surfaces,especially for aAPCs, the special mechanisms of regulation of MHC Ⅱ on aAPCs, and combination therapy targeting MHC Ⅱ as a possible treatment strategy in cancer.

关 键 词：antigen presentation MHC II aAPCs CD4^(+)Th cells 

分 类 号：R730.51[医药卫生—肿瘤]